The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..
decline. Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in
However, Roche is likely to face fierce competition from rival checkpoint inhibitors, namely Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo which have already been on the market ... In fact, Keytruda was first approved for
number of cancer immunotherapies including Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).
The NSCLC market is particularly lucrative, and is currently dominated by Merck &Co’s Keytruda (pembrolizumab), a PD-1 inhibitor which has become a standard treatment for newly-diagnosed NSCLC patients
Lung cancer is otherwise dominated by rival PD-1 inhibitor Keytruda (pembrolizumab), marketed by Merck &Co/MSD. ... Keytruda is the leader in the non-small cell lung cancer (NSCLC) market, which accounts for the majority of lung cancer cases.
[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...